- Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapyChristof Kazda
Lilly Deutschland GmbH, Bad Homburg, Germany
J Diabetes Complications 20:145-52. 2006..To compare the effects of prandial insulin therapy focusing on postprandial glucose control vs. basal insulin therapy focusing on fasting glucose control in patients with type 2 diabetes...
- Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 StudiesChristof M Kazda
Eli Lilly and Company, Suresnes, France
Diabetes Care 39:1241-9. 2016..LY2409021, a potent, selective small-molecule glucagon receptor antagonist that lowers glucose was evaluated for efficacy and safety in patients with type 2 diabetes...
- The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristicsC Kazda
Lilly Deutschland GmbH, 61352 Bad Homburg, Germany
Diabetes Obes Metab 11:1131-7. 2009..To describe the rationale for the European Exenatide (EUREXA) clinical study and describe the characteristics of the patient cohort...
- Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetesThomas Forst
Institute for Clinical Research and Development, Parcusstrasse 8, Mainz D 55116, Germany
J Diabetes Complications 19:128-32. 2005..0 (19.0-49.3) vs. 20.9 (9.7-26.1) AU, P=.0001]. Postprandial microvascular blood flow is disturbed in patients with Type 1 diabetes. Improvement of postprandial metabolic control was found to improve postprandial microvascular function...